In CML, this technology was used to target the BCR-ABL gene where an efficient deletion of the target site was observed, and this was also followed by an increase in apoptosis in CRISPR-EXO3–targeted CML cell line (Vuelta et al., 2020). This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.